Pacific Biosciences of California (PACB) Competitors

Pacific Biosciences of California logo
$1.82 -0.02 (-1.09%)
Closing price 04:00 PM Eastern
Extended Trading
$1.86 +0.04 (+2.36%)
As of 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PACB vs. TXG, FTRE, MRVI, ALMR, and BLFS

Should you buy Pacific Biosciences of California stock or one of its competitors? Pacific Biosciences of California's main competitors and comparable companies include 10x Genomics (TXG), Fortrea (FTRE), Maravai LifeSciences (MRVI), Alamar Biosciences (ALMR), and BioLife Solutions (BLFS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Pacific Biosciences of California compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Pacific Biosciences of California (NASDAQ:PACB) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

10x Genomics has a net margin of -10.84% compared to Pacific Biosciences of California's net margin of -81.31%. 10x Genomics' return on equity of -8.19% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
10x Genomics-10.84% -8.19% -6.46%
Pacific Biosciences of California -81.31%-5,752.12%-19.52%

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$642.82M11.41-$43.54M-$0.52N/A
Pacific Biosciences of California$160.01M3.56-$546.38M-$0.42N/A

10x Genomics has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

10x Genomics presently has a consensus target price of $68.40, suggesting a potential upside of 21.49%. Pacific Biosciences of California has a consensus target price of $2.57, suggesting a potential upside of 41.03%. Given Pacific Biosciences of California's higher probable upside, analysts plainly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics
1 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.22
Pacific Biosciences of California
2 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.60

In the previous week, 10x Genomics had 6 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 13 mentions for 10x Genomics and 7 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.97 beat 10x Genomics' score of 0.24 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
10x Genomics
3 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pacific Biosciences of California
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

84.7% of 10x Genomics shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

10x Genomics beats Pacific Biosciences of California on 11 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Pacific Biosciences of California has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortrea$2.72B0.69-$986.20M-$0.73N/A
Pacific Biosciences of California$160.01M3.56-$546.38M-$0.42N/A

Fortrea has a net margin of -2.58% compared to Pacific Biosciences of California's net margin of -81.31%. Fortrea's return on equity of 13.98% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
Fortrea-2.58% 13.98% 2.76%
Pacific Biosciences of California -81.31%-5,752.12%-19.52%

Fortrea has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market.

Fortrea presently has a consensus target price of $24.23, indicating a potential upside of 23.67%. Pacific Biosciences of California has a consensus target price of $2.57, indicating a potential upside of 41.03%. Given Pacific Biosciences of California's higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than Fortrea.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortrea
2 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.46
Pacific Biosciences of California
2 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.60

In the previous week, Fortrea had 2 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 9 mentions for Fortrea and 7 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.97 beat Fortrea's score of 0.58 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fortrea
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Pacific Biosciences of California
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Fortrea beats Pacific Biosciences of California on 8 of the 15 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Maravai LifeSciences?

Pacific Biosciences of California (NASDAQ:PACB) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

50.3% of Maravai LifeSciences shares are owned by institutional investors. 3.7% of Pacific Biosciences of California shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Maravai LifeSciences has a net margin of -30.83% compared to Pacific Biosciences of California's net margin of -81.31%. Maravai LifeSciences' return on equity of -12.44% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
Pacific Biosciences of California-81.31% -5,752.12% -19.52%
Maravai LifeSciences -30.83%-12.44%-6.66%

Pacific Biosciences of California presently has a consensus price target of $2.57, indicating a potential upside of 41.03%. Maravai LifeSciences has a consensus price target of $8.10, indicating a potential upside of 11.26%. Given Pacific Biosciences of California's higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than Maravai LifeSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacific Biosciences of California
2 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.60
Maravai LifeSciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67

Pacific Biosciences of California has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Maravai LifeSciences has higher revenue and earnings than Pacific Biosciences of California. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Biosciences of California$160.01M3.56-$546.38M-$0.42N/A
Maravai LifeSciences$185.74M10.19-$130.77M-$0.43N/A

In the previous week, Maravai LifeSciences had 4 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 11 mentions for Maravai LifeSciences and 7 mentions for Pacific Biosciences of California. Maravai LifeSciences' average media sentiment score of 1.14 beat Pacific Biosciences of California's score of 0.97 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pacific Biosciences of California
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Maravai LifeSciences
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Maravai LifeSciences beats Pacific Biosciences of California on 12 of the 17 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Alamar Biosciences?

Pacific Biosciences of California (NASDAQ:PACB) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Alamar Biosciences has a net margin of -48.22% compared to Pacific Biosciences of California's net margin of -81.31%. Alamar Biosciences' return on equity of -78.71% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
Pacific Biosciences of California-81.31% -5,752.12% -19.52%
Alamar Biosciences -48.22%-78.71%-20.08%

In the previous week, Pacific Biosciences of California had 1 more articles in the media than Alamar Biosciences. MarketBeat recorded 7 mentions for Pacific Biosciences of California and 6 mentions for Alamar Biosciences. Pacific Biosciences of California's average media sentiment score of 0.97 beat Alamar Biosciences' score of 0.71 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pacific Biosciences of California
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Alamar Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alamar Biosciences has lower revenue, but higher earnings than Pacific Biosciences of California. Alamar Biosciences is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Biosciences of California$160.01M3.56-$546.38M-$0.42N/A
Alamar Biosciences$74.21M28.69-$29.82M-$2.15N/A

Pacific Biosciences of California presently has a consensus target price of $2.57, indicating a potential upside of 41.03%. Alamar Biosciences has a consensus target price of $33.00, indicating a potential upside of 7.70%. Given Pacific Biosciences of California's higher possible upside, equities research analysts plainly believe Pacific Biosciences of California is more favorable than Alamar Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacific Biosciences of California
2 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.60
Alamar Biosciences
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

Summary

Pacific Biosciences of California beats Alamar Biosciences on 7 of the 13 factors compared between the two stocks.

How does Pacific Biosciences of California compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

BioLife Solutions has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

In the previous week, Pacific Biosciences of California had 5 more articles in the media than BioLife Solutions. MarketBeat recorded 7 mentions for Pacific Biosciences of California and 2 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.13 beat Pacific Biosciences of California's score of 0.97 indicating that BioLife Solutions is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioLife Solutions
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pacific Biosciences of California
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

93.2% of BioLife Solutions shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BioLife Solutions presently has a consensus target price of $31.38, suggesting a potential downside of 18.74%. Pacific Biosciences of California has a consensus target price of $2.57, suggesting a potential upside of 41.03%. Given Pacific Biosciences of California's higher probable upside, analysts plainly believe Pacific Biosciences of California is more favorable than BioLife Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLife Solutions
0 Sell rating(s)
10 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.09
Pacific Biosciences of California
2 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.60

BioLife Solutions has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLife Solutions$106.69M17.71-$4.59M$1.1633.28
Pacific Biosciences of California$160.01M3.56-$546.38M-$0.42N/A

BioLife Solutions has a net margin of 53.29% compared to Pacific Biosciences of California's net margin of -81.31%. BioLife Solutions' return on equity of 2.70% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
BioLife Solutions53.29% 2.70% 2.49%
Pacific Biosciences of California -81.31%-5,752.12%-19.52%

Summary

BioLife Solutions beats Pacific Biosciences of California on 11 of the 16 factors compared between the two stocks.

Get Pacific Biosciences of California News Delivered to You Automatically

Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PACB vs. The Competition

MetricPacific Biosciences of CaliforniaLife Sciences Tools & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$569.53M$10.76B$7.74B$11.66B
Dividend YieldN/A1.45%2.46%4.42%
P/E Ratio-4.3351.1734.1729.85
Price / Sales3.568.318.485.62
Price / Cash2.5026.6921.9322.50
Price / Book-9.104.454.373.66
Net Income-$546.38M$57.48B$3.52B$392.18M
7 Day Performance-18.75%-4.88%-5.43%-4.29%
1 Month Performance5.20%-1.03%-4.54%-6.78%
1 Year Performance15.92%20.92%-1.40%-7.10%

Pacific Biosciences of California Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PACB
Pacific Biosciences of California
2.223 of 5 stars
$1.82
-1.1%
$2.57
+41.0%
+14.3%$569.53M$160.01MN/A485
TXG
10x Genomics
2.8403 of 5 stars
$65.05
+9.7%
$68.40
+5.1%
+246.1%$8.80B$642.82MN/A1,178
FTRE
Fortrea
4.189 of 5 stars
$22.24
+1.3%
$23.95
+7.7%
+90.1%$2.01B$2.72BN/A14,300
MRVI
Maravai LifeSciences
1.8979 of 5 stars
$8.02
+6.6%
$7.38
-8.0%
+103.3%$2.00B$185.74MN/A410
ALMR
Alamar Biosciences
2.2088 of 5 stars
$31.84
+13.5%
$33.00
+3.6%
N/A$1.90B$74.21MN/A222

Related Companies and Tools


This page (NASDAQ:PACB) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners